The Penny Stock Of Cytokinetics (CYTK) At $2.50? Yeah, Right

Yesterday, the Wall Street analyst firm of Needham & Co. initiated coverage on Cytokinetics Inc. (CYTK) issuing a “Buy” rating and a $2.50 price target. The  biopharmaceutical penny stock has not seen $2.50 in over 18 months and just agreed to sell an additional 55.92 million shares with 33.55 million attached warrants to Cowen and Co. LLC for $56 million. Seeing as ...

Continue Reading →
0